In a series of 153 children with T-cell malignancies enrolled in 2 consecutive EORTC trials, we assessed the HOX11L2 expression and/or the presence of a t(5;14)(q35;q32). Additionally, in 138 of these patients, HOX11 expression and SIL-TAL rearrangement were also assessed. These alterations were mutually exclusive and their frequency was 23% (n=35), 7% (n=10) and 12% (n=17) respectively. HOX11L2/t(5;14) positivity was more frequent in ALL with cortical Timmunophenotype and in children between 6 and 9 years of age. In contrast with previously reported data, HOX11L2/t(5;14) positive and negative patients were comparable with regard to clinical outcome as well as to the response to a 7-day prephase treatment or to residual disease at completion of induction therapy. The 3-year event-free survival (EFS) rate (±SE%) for HOX11L2/t(5;14) positive and negative patients was 75.5% (±8.1%) and 68.3% (±5.0%) respectively; the hazard ratio was 0.84 [95% confidence interval (0.40, 1.80)]. Patients with HOX11-high expression and those with SIL-TAL fusion had low levels of residual disease at the end of induction and a favorable prognosis: the 3-year EFS rate was 83.3% (±8.5%) and 75.3% (±12.6%) respectively. The results obtained in HOX11L2/t(5; 14) patients in this study do not confirm the unfavorable prognosis reported in previous studies.
Introduction
Childhood T-cell malignancies include T-ALL, which accounts for approximately 15% of ALL, and T-cell lymphoblastic lymphoma, which represents about one third of non-Hodgkin's lymphoma. As compared to precursor B ALL, T-cell malignancies are often associated with unfavorable features. The use of more intensive treatments and risk-adapted therapy have significantly improved the outcome of patients with T-ALL as well as of patients with T-cell lymphoblastic lymphoma, and event free survival rates of 60% to 70% are now reported in children 1, 2 . Whether classical risk factors such as age or WBC are relevant in patients with T-ALL is a matter of debate. A study of the Pediatric Oncology Group suggested that the prognostic significance of initial features such as age, leukocyte count, involvement of CNS is reduced in Tlineage ALL as compared to B-lineage ALL 3 . Some genetic abnormalities present in the leukemic clone of B-lineage ALL are of strong prognostic importance. However, there are only few data concerning the possible prognostic significance of genetic abnormalities in T-lineage malignancies.
Some non-random translocations that are specific to T-lineage malignancies have been identified. They involve genes that code for transcriptional regulators and are transcriptionally deregulated in malignancies.
Alteration of the TAL-1 (SCL; TCL-5) locus located on chromosome 1p32 is considered as the most common nonrandom genetic defect in childhood T-ALL. In 1 to 3% of childhood T-ALL, TAL-1 disruption is associated with a t(1;14)(p33;q11) 4, 5 . In another 9% to 26% of T-ALL, TAL-1 defect occurs via a nonrandom submicroscopic interstitial deletion between a locus called SIL and the 5'UTR of TAL-1, giving rise to a SIL-TAL fusion transcipt 6, 7 . Both alterations disrupt the coding potential of TAL-1 in a similar manner, leading to its ectopic expression in T-cells 8, 9 .
For personal use only. on June 7, 2017 . by guest www.bloodjournal.org From Two other translocations, t(10;14)(q24;q11) and its variant t(7;10)(q35;q24) were identified in T-ALL. Either of these is present in about 5% of cases. They both lead to the transcriptional activation of an homeobox gene HOX11 (TLX1; TCL3) which is not expressed in normal Tcells 10, 11 , by bringing the HOX11 coding sequence under the transcriptional control of regulatory sequences of the T-cell receptor gene 10, [12] [13] [14] . Overexpression of HOX11 has also been demonstrated in the absence of a 10q24 rearrangement suggesting that other mechanisms can lead to this aberrant gene expression 11, 15 .
Recently, a new cryptic translocation, t(5;14)(q35;q32) was found in T-ALL by FISH 16, 17 .
This translocation leads to the ectopic expression of another homeobox gene, HOX11L2 (RNX; TLX3), possibly by bringing it under the influence of regulatory elements of CTIP2, a gene highly expressed during T lymphoid differentiation 16 . Ectopic expression of HOX11L2 has also been found in a subset of T-ALL by quantitative RT-PCR 15 . HOX11 and HOX11L2 are called orphan homeobox genes because they are located outside of the 4 mammalian HOX clusters. They are members of a class of homeobox genes that also includes the mammalian HOX11L1 (ENX; TLX2) gene 18 . Preliminary studies indicate that t(5;14) is restricted to T-lineage ALL and is more frequent in children than in adults. It could represent a frequent specific genetic alteration in childhood T-ALL 19, 20 . Moreover, t(5;14) and/or HOX11L2 ectopic expression have been reported as being associated with a very poor outcome in children with T-ALL 15, 19 .
The aim of our study was to retrospectively evaluate the frequency and prognostic value of the newly described t(5;14) and/or HOX11L2 expression in childhood T-cell malignancies. For this purpose, we studied blastic samples from 153 children with newly diagnosed T-cell malignancies enrolled in 2 consecutive EORTC-CLG ALL studies. We also reassessed the frequency of two additional alterations specifically found in T-ALL which have not been extensively investigated in children, HOX11 overexpression and SIL-TAL fusion, as well as their possible association with a distinct leukemic phenotype and/or outcome.
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Patients and methods

Patients
Eleven of these children were previously included in the study of Mauvieux et al 20 .
T-cell lineage was defined by the presence of the T-cell antigen CD3 either on the cell surface (sCD3), or in the cytoplasm (cCD3). At least 2 of the following B-cell markers tested (CD19, s/cCD22, cCD79a), and at least 3 of the following myeloid markers tested (CD13, CD33, CD117, MPO) had to be negative. Subclassification of T-cell lineage was performed as follows. Tcell malignancies positive for cCD3, CD7, +/-CD2, +/-CD5, +/-CD8 and negative for sCD3 and CD1a were considered "early-T". When positive for CD1a, T-cell malignancies were considered "cortical-T", and when positive for CD3 but negative for CD1a they were considered "mature-T".
Karyotyping of malignant clone at diagnosis was centrally reviewed.
For patients with T-ALL, the hematologic status after the prephase (one intrathecal methotrexate injection on day 1 and 7 days of glucocorticoid treatment), conventionally called "response" to the prephase, was assessed on day 8 by the number of leukemic blasts: patients with 
Detection of the t(5;14)(q35;q32) by FISH
All samples analyzed by FISH were collected from bone marrow or lymph node samples with major blastic involvement. FISH analyses for detection of the t(5;14) were carried out on cytogenetic pellets and interpreted as positive when metaphases with t(5;14) were present.
The t(5;14)(q35;q32) was detected using the combination of signals obtained with a chromosome 14 painting (wcp14) and with the 885A6 YAC assigned at 5q35. The rhodamine direct labeled wcp14 was purchased from Oncor (CP5614-RW Appligene Oncor, Gaithersburg, MD) and used according to manufacturer's instructions. The 885A6 YAC was obtained from the CEPH library (Fondation Jean Dausset -CEPH, Paris, France). The YAC and the wcp14 were either cohybridized or sequentially hybridized on the same slide, and hybridizations were carried out according to methods previously described 24 . Metaphases with a t(5;14) were characterized by a splitting of one YAC signal, one part translocating onto the telomeric end of a chromosome 14
(green signals in Figure 1 ). The wcp14 (red signal in Figure 1 ) pointed at the derivative 14 as well as at the derivative 5, characterized by a small translocated fragment from chromosome 14 at its telomeric part. In section a, the derivative 14 (der 14) is identified by a green signal at its telomeric end (14q32), corresponding to the translocated part of the YAC. In section b, the derivative 14 and the normal chromosome 14 are identified by wcp14 (red signal).
Sample preparation for RNA analysis
For each patient, a sample of malignant cells was collected on EDTA at diagnosis, according to the EORTC-CLG protocol. It consisted of bone marrow for ALL patients, and of pleural liquid or lymph node punctuate or bone marrow (in stage IV) for lymphoma patients. In case of bone marrow sampling, mononuclear cells were separated by Ficoll centrifugation, counted and stored at -80°C.
The percentage of blasts after Ficoll separation was evaluated on a cytospin. Total RNA was For personal use only. on June 7, 2017 . by guest www.bloodjournal.org From extracted using RNA Plus (Appligene, Illkirch, France), according to the instructions of the manufacturer. Determination of the quality and approximate concentration of total RNA was performed by electrophoresis on a 0.8% agarose gel stained with ethidium bromide.
cDNA synthesis was performed using random hexamers, as previously described 25, 26 . Each series of RT included one tube with yeast tRNA as a negative control and positive controls consisting in 10 -3 dilutions of RNA samples positive for the different targets. France) in a total reaction volume of 50 µl. PCR was performed on the ABI PRISM 7700
SIL-TAL RT-PCR
Sequence detector system (Applied Biosystems). After 10 min at 95°C, 50 cycles (15 s at 95°C and 15 s at 65°C) were performed. All experiments were done in duplicate. The threshold cycle (Ct), defined as the fractional cycle number at which the signal reached a pre-set threshold was measured in each sample for the target and control (TBP) cDNA.
Samples displaying a TBP Ct (Ct TBP ) higher than 30 were considered as degraded and were discarded. When good quality RNA was available, results obtained for HOX11 and HOX11L2 transcripts were compared to those obtained for TBP transcripts, which were used as a reference, by calculating the delta Ct ( Ct HOX11L2-TBP and Ct HOX11-TBP ) for each sample.
When present, HOX11L2 expression was unambiguous in virtually all cases, with expression levels equal or higher than those obtained for TBP ( Ct HOX11L2-TBP ranging from -5.5 to 0.6, mean - 
HOX11L2
HOX11
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Statistical analysis
Event-free survival was calculated from the date of complete remission to the date of first relapse or death. For patients who failed to reach complete remission by the end of inductionconsolidation, the failure was considered as an event at time 0. All patients alive and in first continuous remission were censored at their last follow-up. The duration of survival was calculated from the date of start of treatment until the date of death; patients still alive were censored at their last follow-up.
Actuarial curves were calculated according to the Kaplan-Meier technique 29 . The curves have been cut at 8 years because too few patients remained at risk beyond that time point; one relapse occurring at 9 yrs has therefore not been displayed. The standard errors (SE) of the estimates were computed using the Greenwood formula 29 . The differences between actuarial curves were tested for statistical significance using the two-tailed log-rank test factor. The Cox proportional hazards model has been used to obtain the estimate and the 95% confidence interval of the hazard ratio (HR) of the instantaneous event rate in one group vs. the one in another group, as specified by a given variable, and the Wald test has been used to determine the prognostic significance 29 . The Cox model has also been used to determine the independent prognostic importance of several variables. All analyses were based on the intent-to-treat principle. ;14), and only 3 (5%) patients showed HOX11L2 expression without evidence of t (5;14).
Frequency of genetic alterations in T-ALL and T-lymphoblastic lymphoma
Expression of HOX11L2 and/or t(5;14) was found in 34 (24.1%) of 141 T-ALL and in one (8.3%) of 12 T-lymphoblastic lymphoma patients. Of the 153 patients tested for HOX11L2 expression and/or t(5;14), 138 could also be studied for the presence of HOX11 expression or of SIL-TAL fusion. Of the 127 patients with T-ALL, 9 (7.1%) displayed high HOX11 expression and 15 (11.8%) SIL-TAL fusion. Of the 11 patients with lymphoblastic lymphoma, 1 (9.1%) displayed high HOX11 expression and 2 (18.2%) SIL-TAL fusion. In this group of 138 patients, a combination of two or three of these abnormalities was never observed.
Characteristics of children with T-cell malignancies according to genetic subgroups
Among the 138 patients in whom all 3 genetic alterations could be investigated, four subgroups were distinguished: the HOX11L2 group contained patients displaying either a t (5;14) and/or HOX11L2 expression (n=35), the HOX11-high group those exhibiting high HOX11 expression (n=10), the SIL-TAL group those who were positive for the SIL-TAL fusion (n=17), and the group "other", containing those displaying none of these abnormalities (n=76). In addition, a fifth group containing all patients with HOX11L2 negative expression, irrespective of their HOX11 or SIL-TAL status has been analyzed (n=118).
Characteristics of the patients according to genetic subgroups are described in Table 1 . No significant difference in sex ratio or of incidence of mediastinal involvement was observed between these genetic subgroups. The median age was 6, 5, 11 and 8.5 years in these 4 groups, respectively, which is not significantly different (Kruskal-Wallis p=0.13) ( Table 1 ). However, the age distribution was slightly different between the four groups ( Figure 3) . The age of patients with a HOX11L2 positive ALL displayed a symmetric distribution, 48.6% of them being 6-9 years old at diagnosis, whereas in the HOX11-high group, no patient was present in this age category. The frequency of SIL-TAL positive T-cell malignancies increased regularly with age to reach 53% in children older than 10 years at diagnosis.
White blood cell count (WBC) at diagnosis was higher (Kruskal-Wallis p=0.12) for patients of the SIL-TAL group as compared to the HOX11L2, HOX11-high, and "other" groups of patients: the medians were 124 G/L, 34, 29 and 51 respectively. 
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Detailed immunophenotyping was available in 100 out of 138 patients: 24 were categorized as early, 44 as cortical, and 32 as mature-T lineage. Even though HOX11-high and HOX11L2 malignancies were predominantly associated with a cortical-T phenotype, phenotype was rather heterogeneous in the HOX11L2 group with 25% of the cases displaying a mature-T phenotype.
Patients with a SIL-TAL fusion had an immunophenotyping distribution very similar to that of the entire group. Overall, there was no association between the genetic subgroup and immunophenotype maturation (p=0.95).
Cytogenetic evaluation was successful in 111 out of 127 ALL patients, the karyotype failure/unknown rate ranging from 0% in HOX11-high patients to 18.8% in the "other" group.
Forty-eight (43.2%) out of these 111 patients had a normal karyotype when using conventional cytogenetic techniques. Thirty (62.5%) of these 48 patients with a normal karyotype had a genetic abnormality: 21 (43.8%) had a HOX11L2, 5 (10.4%) HOX11 and 4 (8.3%) a SIL-TAL alteration. In the majority of HOX11L2 and HOX11-high malignancies, no cytogenetic alteration was found whereas SIL-TAL fusion was more often associated with additional cytogenetic alterations (KruskalWallis p=0.02). Surprisingly, none of the 9 cases with a high HOX11 expression and a successful karyotype displayed a t(10;14) or a 10q24 rearrangement.
For 
Prognosis associated with t(5;14) and/or HOX11L2 expression
The group of 153 patients included in the study had overall 3-year EFS and survival rates of 70.0% and 75.8%, respectively. These outcome data are similar to those observed for the whole population of patients with T-cell malignancies included in the 58881 and 58951 trials during the same period of time. The clinical outcome of patients from the HOX11L2 group was similar to that of the patients who did not display this abnormality ( Figures 4A and 4B) : the 3-year EFS (±SE) was 75.5% (±8.1%) and 68.3% (±5.0%), respectively, and the 3-year overall survival was 77.3% (±8.4%) and 75.3% (±4.6%), respectively. The estimated hazard ratios for these 2 analyses are close to 1, and the upper 95% confidence intervals are lower than 2, indicating that the HOX11L2 positive patients have not a clearly worse outcome than HOX11L2 negative patients. The pattern of events (No CR, type of event) was quite similar in the 2 groups (Table 2A and Table 2B ).
In T-ALL patients, the rate of "response" to prephase did not differ significantly (KruskalWallis p=0.24) between HOX11L2 positive and negative patients (Table 2A) The impact of some initial factors on the outcome was limited. The 3-year EFS of patients with a WBC > 50 G/l (n=77) was 64.3% vs 76.3% (p=0.07) for patients with a WBC < 50 G/l (n=76), and the estimated hazard ratio was 1.8; the 3-year EFS of patients with a High NCI Risk (n=104) or Standard NCI Risk (n=49) were 71.1% and 68.4% respectively. On the other hand, in T-ALL patients, those with a good "response" to prephase (n=91) had a better outcome than those with a poor "response" (n=49): the 3-year EFS rates were 81.9% and 47.5% (p<0.001) respectively, the estimated hazard ratio was 4.39, and the 95% CI was (2.22 , 8.69 ). The Cox model indicated that the differences between HOX11L2 positive and negative in terms of EFS remained practically For personal use only. on June 7, 2017 . by guest www.bloodjournal.org From
Prognosis according to genetic subgroups
Restricting the analyses to the subgroup of 138 patients for whom a genetic group could be determined (HOX11L2, HOX11-high, SIL-TAL or "other"), the overall results were practically identical to the overall group of 153 patients: the 3-year EFS and survival rates were 70.4% and 75.3%, respectively. The prognostic impact of the genetic group was not significant, either in terms of EFS or Survival ( figure 5A and 5B). The 3-year EFS and survival rates in the 4 groups and the estimates of the hazard ratios, considering the "other" group as baseline, are given in Table 4 The clinical outcome of patients from the HOX11-high group was quite good ( Figure 4A and 4B). Only one child had a combined CNS relapse, 30 months after the achievement of CR. This good outcome is consistent with the results obtained when studying in vivo sensitivity to the early steps of chemotherapy. None of the children of the HOX11-high group were poor responders to prephase, and none of them had high levels of MRD after completion of induction therapy (Table   2A ).
SIL-TAL positive patients had a particularly high frequency (50%) of poor "response" to the prephase, but none of them had high levels of MRD one month later (Table 2A) . Out of 15 SIL-TAL positive patients, 2 had a BM relapse and one had an early toxic death.
In lymphoblastic lymphoma patients the outcome was extremely favorable regardless the genetic group (Table 2B) Figure 5B
Discussion
Childhood B-lineage ALL harbors different non-random chromosomal translocations that identify phenotypically and clinically distinct subgroups of patients. In contrast, T-ALL are infrequently characterized by chromosomal translocations, although several T-cell specific genetic alterations have been described that correlate with different stages of thymocyte differentiation. 30 . In this respect it could lead to HOX11L2 transcription deregulation, but this hypothesis has not been tested so far. However, none of our patients displaying high HOX11L2 levels without t(5;14)(q35;q32) displayed a t(5;14)(q33;q11).
Our study suggests that the outcome of the children with a HOX11L2/t(5;14)(q35;q32)
positive T-cell malignancies was similar to that observed in children with other T-cell malignancies.
The p-value was not significant, but with a total of 39 events, the statistical power in detecting a difference between 2 groups in term of EFS rate at 3 yrs of 20% (50% vs 70%: hazard ratio = 1.94)
is only 50%; for a difference of 40% (30% vs 70%: hazard ratio = 3.38) it is approximately 90%.
The ectopic expression of HOX11L2 is probably not associated with the poor prognosis previously reported by other studies 15, 19 . Our study was larger than the latter, the median follow-up was 3.1 years, and the EFS analysis was based on 39 events vs 6 events 19 . Therefore, the estimate of the hazard ratio of patients with HOX11L2 positive vs negative is still unreliable, the 95% confidence interval is quite wide, (0.40, 1.84), but it does not cover 2, which represents the minimum level for a prognostic factor. Actually, the data are compatible with the hypothesis that HOX11L2 may be associated with a good prognosis. Two thirds of HOX11L2 positive group had a cortical-T immunophenotype (CD1a+) vs 39% in HOX11L2 negative patients. CD1a+ T-ALL has been identified as a distinct subgroup with an excellent prognosis under different treatment, including the BFM 3, [31] [32] [33] . In this study as well, there was a trend in favor of better prognosis for CD1a+ patients.
This good prognosis has been shown to be associated with an increased in vitro sensitivity to dexamethasone and doxorubicin 34 . In contrast, the most immature T-ALL (CD1a-/CD3-), as well as mature T-cells (CD1a-/CD3+) are associated with a worse outcome 3, [31] [32] [33] 35 . The presence of a high proportion of HOX11L2 expressing ALL within the immunological subset associated with a favorable prognosis in several treatment protocols provides an indirect argument against the For personal use only. on June 7, 2017 . by guest www.bloodjournal.org From association of HOX11L2 expression with a very unfavorable outcome in most of the current treatment protocols for T-ALL.
In addition to HOX11L2, SIL-TAL fusion and HOX11 expression were investigated in 138 children. A combination of any of these three abnormalities was never observed, suggesting that they are mutually exclusive. This observation as well as the fact that HOX11L2 and HOX11 transcriptional deregulations are preferentially observed in patients with normal karyotypes are in favor of the involvement of these genes in the initiation of leukemogenesis.
The frequency of SIL-TAL fusion is usually considered to be around 25% in children but reported frequencies vary widely, ranging from 9% to 30% depending on the study. The 12% frequency we observed for SIL-TAL fusion is in the lower range of this spectrum. However, if we make a compilation of results obtained in studies gathering more than 70 patients, including ours, we obtain a mean estimation of only 17% for SIL-TAL frequency in childhood T-ALL, suggesting this frequency has probably been overestimated in the past 6, [36] [37] [38] [39] . A possible explanation is that, as shown in our and other studies, SIL-TAL positive patients usually display a high WBC and could be preferentially selected in retrospective studies, depending on the availability of stored material. The regular increase in SIL-TAL frequency with age that we observed is surprising since this defect is rarely seen in adult malignancies 6, 39, 40 . In this respect, it may be interesting to know whether the few cases found in adults are preferentially found in younger patients. A recent study, which reports SIL-TAL frequencies of 16% in adults between 16 and 30 years old, and 5% for adults older than 30,
suggests that it could be the case 39 . Variations of SIL-TAL frequencies with age may contribute to the differences in frequencies observed from one pediatric study to another since some included children up to 15 and others up to 20 years of age.
Very few data are available concerning the prognostic implication of SIL-TAL fusion in childhood T neoplasms. A trend toward improved EFS for patients displaying SIL-TAL fusion was reported in two studies 38,41 including 48 and 9 positive patients, respectively. No data are available for SIL-TAL positive patients treated according to more recent protocols, in which higher overall EFS rates are obtained for patients with T-cells ALL. Although our study did not show a higher EFS rate for SIL-TAL positive patients, there was a trend toward a better survival rate. There was a discrepancy between the high frequency of poor "response" to the prephase and the good MRD results after induction in these patients. Actually, the discrepancy was only apparent, because the post-prephase blast count in the peripheral blood, conventionally but inappropriately designated as "response", is not a true measure of blast sensitivity to the prephase but also depends on the initial blast count. As SIL-TAL-positive patients tend to display higher initial WBC, even with equal sensitivity to the prephase, a higher percentage of so called "poor responders" should be expected.
Translocation (10;14) is a non-random alteration observed in both T-ALL and T-cell lymphoblastic lymphomas 42 . It leads to high HOX11 expression. There is some evidence that HOX11 may play an important role in leukemogenesis. In particular, it has been shown that constitutive expression of HOX11 favors expansion and, in some instances, immortalization of murine hematopoietic progenitors in vitro 43, 44 . T(10;14) has been found with a frequency of 1.7% to 3.5% in childhood T-ALL 5 . Salvati et al. 11 reported overexpression of HOX11 in 4 out of 12 pediatric T-ALL and showed one case of HOX11 overexpression lacking t(10;14). More recently, Ferrando et al. 15 , using a microarray approach, observed high levels of HOX11 transcript in 8 of 59
(13%) pediatric T-ALL, and half of them only displayed a 10q24 rearrangement. In our study, none of the children expressing high levels of HOX11 had a 10q24 rearrangement. These data strongly suggest that in many T-ALL, another genetic abnormality is responsible for deregulation of HOX11 transcription. Although mutation of negative regulatory elements was never found, epigenetic reactivation by specific demethylation of HOX11 promoter has been shown in ALL expressing HOX11 in the absence of 10q24 rearrangements 45 .
A large study of childhood T-ALL demonstrated the association of t(10;14) with a better survival in univariate analysis as compared with other chromosomal alterations 5 . A favorable
For personal use only. on June 7, 2017 . by guest www.bloodjournal.org From outcome was also observed in the study by Ferrando et al. 15 in which the criteria was HOX11 expression instead of the presence of the t(10;14). T(10;14) is more frequent in adults than in children, and frequencies of 14% have been reported 46 while preliminary data on HOX11 expression show 30% of positivity 47 . In adults also, this translocation as well as HOX11 overexpression seem to be associated with a favorable outcome. In our series of children with T-ALL, we also found a clear trend toward a better outcome for children displaying a high HOX11 expression, in keeping with a good in vivo response to the early steps of chemotherapy. Due to the rarity of this genetic alteration, all studies, including ours, lacked the statistical power which would have allowed any definitive conclusion about its prognostic significance. Further data are required to establish whether the seemingly better outcome associated with t(10;14) and/or HOX11 overexpression is indeed real.
We studied 12 cases of T-cell lymphoblastic lymphoma. Childhood lymphoma remains relatively unexplored at the cytogenetics and molecular levels. Lymphoblastic lymphoma can in some cases evolve into a leukemic phase morphologically indistinguishable from T-ALL, and, in children, malignant blasts present in lymphoblastic leukemia and in ALL share common phenotypic features. During the period covering our study, ALL and lymphoblastic lymphomas were treated according to the same protocols 2 . However, whether ALL and lymphoblastic lymphoma do or do not represent the same disease is still unclear. Kikuchi et al 41 having failed to find TAL-1 disruption in 18 cases of T-cell lymphoblastic lymphoma concluded that this alteration was restricted to T-ALL. In our study, the three T-cell specific alterations investigated that were observed in ALL were also found in lymphoblastic lymphoma, including SIL-TAL. This is consistent with ALL and lymphoma representing different clinical presentations of the same disease. However, HOX11L2 positivity was found in only one case of T-cell lymphoblastic lymphoma. Although the small number of cases studied precludes any definitive conclusion, HOX11L2 overexpression could be less frequent in T-cell lymphoblastic lymphomas than in T-ALL, the more so as T-cell
For personal use only. on June 7, 2017 . by guest www.bloodjournal.org From lymphoblastic lymphomas, including those we studied, generally have a cortical thymocyte phenotype which is preferentially associated with HOX11L2 transcriptional deregulation in ALL.
In conclusion, our study provides additional data in favor of a good prognosis associated with SIL-TAL fusion and with high HOX11 expression in childhood T-ALL. This is consistent with MRD results obtained in these patients and in line with the high predictive power of MRD in T-ALL that was observed in this study (data not shown) and others 49 . In contrast with previous reports, which were based on much smaller number of patients and shorter follow-up, we did not find that children with HOX11L2 expressing ALL had a worse outcome than others. However, as prognosis associated with genetic alterations may vary according to the treatment regimen, more extensive studies are clearly required before definitive conclusions can be drawn.
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